Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1896
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment ; day:15 ; month:7 ; year:2020 ; pages:1-13
Applied health economics and health policy ; (15.7.2020), 1-13
- Classification
-
Wirtschaft
- Creator
-
Shaikh, Mujaheed
Giudice, Pietro Del
Kourouklis, Dimitrios
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40258-020-00601-9
- URN
-
urn:nbn:de:101:1-2020091118453834410874
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shaikh, Mujaheed
- Giudice, Pietro Del
- Kourouklis, Dimitrios
- SpringerLink (Online service)
Other Objects (12)
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Price markups and R&D inputs: The pharmaceutical industry in Finland and the USA
Revisiting super-cycles in commodity prices
R&D in the Belgian Pharmaceutical Sector
Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
Revisiting Social Discount Rates for Public Investment
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry
Cash-constrained R&D Investment
Does public scientific research complement industry R&D investment? : the case of NIH supported basic and clinical research and pharmaceutical industry R&D
Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Price markups and R&D inputs: The pharmaceutical industry in Finland and the USA
Revisiting super-cycles in commodity prices
R&D in the Belgian Pharmaceutical Sector
Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
Revisiting Social Discount Rates for Public Investment
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry
Cash-constrained R&D Investment
Does public scientific research complement industry R&D investment? : the case of NIH supported basic and clinical research and pharmaceutical industry R&D
Does Public Scientific Research Complement Industry R&D Investment? The Case of NIH Supported Basic and Clinical Research and Pharmaceutical Industry R&D
Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment
Price markups and R&D inputs: The pharmaceutical industry in Finland and the USA
Revisiting super-cycles in commodity prices
R&D in the Belgian Pharmaceutical Sector
Public funding and private investment for R&D: a survey in China’s pharmaceutical industry
Revisiting Social Discount Rates for Public Investment
Pharmaceutical patents: incentives for R&D or marketing?
R&D Spin-outs in the pharmaceutical industry
Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry
Cash-constrained R&D Investment
Does public scientific research complement industry R&D investment? : the case of NIH supported basic and clinical research and pharmaceutical industry R&D